Literature DB >> 2112538

In-vitro synergy testing of nine antimicrobial combinations against Listeria monocytogenes.

A P MacGowan1, H A Holt, D S Reeves.   

Abstract

In-vitro antimicrobial synergy against Listeria monocytogenes was assessed using nine combinations in chequerboard (bacteriostatic) tests and time-kill (bactericidal) studies. Ampicillin/gentamicin and trimethoprim/sulphamethoxazole were the most synergistic combinations in bacteristatic tests, whereas gentamicin with ampicillin, trimethoprim or vancomycin and trimethoprim/sulphamethoxazole were the most synergistic in bactericidal tests. Gentamicin-containing combinations were most effective at killing L. monocytogenes and those containing rifampicin least effective.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112538     DOI: 10.1093/jac/25.4.561

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Antibiotic resistance in Listeria spp.

Authors:  E Charpentier; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

Review 2.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  In vitro demonstration of transport and delivery of antibiotics by polymorphonuclear leukocytes.

Authors:  M O Frank; G W Sullivan; H T Carper; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 4.  Listeria Monocytogenes infections.

Authors:  R C Gordon
Journal:  Indian J Pediatr       Date:  1995 Jan-Feb       Impact factor: 1.967

Review 5.  Management of listeriosis.

Authors:  H Hof; T Nichterlein; M Kretschmar
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 6.  Antimicrobial chemotherapy of human infection due to Listeria monocytogenes.

Authors:  E M Jones; A P MacGowan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.